Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 6/20 | 0.49 |
| ▸ | NOS1 | P29475 | 5/20 | 0.49 |
| ▸ | NOS3 | P29474 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Nio SCHEMBL1569333 | 1.00 | OTC (0.54) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nio SCHEMBL5287105 | 1.00 | OTC (0.54) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nio SCHEMBL676367 | 0.98 | OTC (0.53) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nio SCHEMBL7662264 | 0.98 | OTC (0.53) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nio SCHEMBL1320520 | 0.98 | OTC (0.53) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nio SCHEMBL676368 | 0.98 | OTC (0.53) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nio SCHEMBL1320518 | 0.98 | OTC (0.53) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nio SCHEMBL29156210 | 0.98 | OTC (0.53) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nil SCHEMBL322091 | 0.95 | ARG2 (0.50) | OTCNOS2NOS1NOS3MEN1 | |
| L-Nil SCHEMBL934874 | 0.95 | ARG2 (0.50) | OTCNOS2NOS1NOS3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-09-04 | — | — | US | claimed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-09-26 | — | — | US | claimed |
| WO-2005060437-A2 | COMPOSITION COMBINATIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | claimed |
| WO-2005041886-A2 | METHODS FOR GENERATING OR INCREASING REVENUES RELATED TO PAIN INHIBITOR COMMERCE | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| WO-2005041894-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| CN-1326785-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2001-12-19 | — | — | CN | claimed |
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-09-04 | — | — | US | disclosed |
| US-12251449-B2 | Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20240166994-A1 | OLIGODENDROCYTE PROGENITOR CELL COMPOSITIONS | ASTERIAS BIOTHERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008027377-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF INFLUENZA VIRUS- INDUCED PULMONARY IMMUNE PATHOLOGY | DUKE UNIVERSITY (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2005060437-A2 | COMPOSITION COMBINATIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005041894-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041886-A2 | METHODS FOR GENERATING OR INCREASING REVENUES RELATED TO PAIN INHIBITOR COMMERCE | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| CN-1326785-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2001-12-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | OTC 3529/4885NOS2 4651/4885NOS1 4693/4885 |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, SMN1; SMN2 | OTC 10/4885NOS2 17/4885NOS1 28/4885 |
| US-12251449-B2 | Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase | STING1, CGAS, GMPS | OTC 1970/4885NOS2 7/4885NOS1 4/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | OTC 1/4885NOS2 356/4885NOS1 558/4885 |
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | STING1, CGAS, GMPS | OTC 1970/4885NOS2 7/4885NOS1 4/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | OTC 1/4885NOS2 356/4885NOS1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.